可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Genoux A, Dehondt H, Helleboid-Chapman A, et al. Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalpha[J]. Arterioscler Thromb Vasc Biol, 2005, 25(6):1186-1192.
[2] Prieur X, Huby T, Coste H, et al. Thyroid hormone regulates the hypotriglyceridemic gene APOA5[J]. J Biol Chem, 2005, 280(30):27533-27543.
[3] Nowak M, Helleboid-Chapman A, Jakel H, et al. Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor[J]. Mol Cell Biol, 2005, 25(4):1537-1548.
[4] O’Brien PJ, AlbornWE, Sloan JH, et al. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins[J]. Clin Chem, 2005, 51(2):351-359.
[5] Ishihara M, Kujiraoka T, Iwasaki T, et al. A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration[J]. J Lipid Res, 2005, 46(9):2015-2022.
[6] 刘琼,赵水平. 人载脂蛋白AV多克隆抗体的制备和组织分布[J]. 中国实用内科杂志, 2006, 26(16):1275-1278.
[7] 胡松,赵水平,刘琼,等. 人血清载脂蛋白AV的检测及与血脂的相关性[J]. 中国动脉硬化杂志, 2007, 15(2):145-147.
[8] Rensen PC, van Dijk KW, Havekes LM. Apolipoprotein AV: low concentration, high impact[J]. Arterioscler Thromb Vasc Biol, 2005, 25(12):2445-2447.
[9] Olofsson SO. ApoA-V: the regulation of a regulator of plasma triglycerides[J]. Arterioscler Thromb Vasc Biol, 2005, 25(6):1097-1099.
[10]Merkel M, Loeffler B, Kluger M, et al. Apolipoprotein AV acceleratesplasma hydrolysis of triglyceride-rich lipoproteins by interaction withproteoglycan-bound lipoprotein lipase[J]. J Biol Chem, 2005, 280(22):21553-21560.
[11]Loredan SN, Jamila FN, Jean-Charles F, et al. Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome[J]. Clin Chem Lab Med, 2007, 45(9):1133-1139.
[12]Oliva CP, Pisciotta L, LiVolti G, et al. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia[J]. Arterioscler Thromb Vasc Biol, 2005, 25(2):411-417.
[13]Dorfmeister B, Zeng WW, Dichlberger A, et al. Effects of Six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding[J]. Arterioscler Thromb Vasc Biol, 2008, 28(10):1866-1871.
[14]Tang Y, Sun P, Guo D, et al. A genetic variant c. 553G>T in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and altered triglyceride levels in a Chinese population[J]. Atherosclerosis, 2006, 185(2):433-437.
[15]Dallongeville J, Cottel D, Montaye M, et al. Impact of APOA5/A4/C3 genetic polymorphisms on lipid variables and cardiovascular disease risk in French men[J]. Int J Cardiol, 2006, 106(2):152-156.
[16]桑震池,陈书艳. 他汀类药物、烟酸、抗氧化剂对降脂和冠状动脉粥样硬化的作用[J] . 心脏杂志, 2008, 20(4):487-490.